Lexiscan(r) (regadenoson)

The standard adult dosage for regadenoson is a fixed dose of 0.4 mg (5 mL). Unlike many other medications used in cardiac imaging, regadenoson does not require weight-based calculations for adult patients. This fixed-dose approach simplifies administration and reduces the potential for dosing errors. The medication is delivered as a rapid intravenous bolus (usually over 10 seconds) into a peripheral vein using a standard catheter. Following the injection of regadenoson, a saline flush (5 mL of 0.9% Sodium Chloride) is immediately administered to ensure the full dose enters the circulation. The radiopharmaceutical (the imaging tracer) is then typically injected approximately 10 to 20 seconds after the saline flush.

The safety and effectiveness of regadenoson in pediatric patients (under the age of 18) have not been established. Clinical trials focusing on the pediatric population are limited. Consequently, healthcare providers generally avoid using regadenoson in children unless specifically directed by a pediatric cardiologist in a research or highly specialized setting. In most cases, alternative methods for assessing heart function are preferred for younger patients.

Renal Impairment

No dosage adjustment is required for patients with renal (kidney) impairment, including those with end-stage renal disease or those undergoing dialysis. Clinical studies have shown that while the clearance of the drug may be reduced in patients with severe kidney disease, the single-dose nature of the administration does not necessitate a change in the 0.4 mg dose.

Hepatic Impairment

The pharmacokinetics of regadenoson have not been specifically studied in patients with hepatic (liver) impairment. However, because the drug is primarily excreted unchanged by the kidneys and does not undergo significant liver metabolism, dosage adjustments are generally not considered necessary for patients with liver disease.

Elderly Patients

In clinical trials, no overall differences in safety or effectiveness were observed between subjects aged 65 and over and younger subjects. While older patients may have decreased renal function, the standard 0.4 mg dose remains the clinical recommendation. However, elderly patients may be more sensitive to the transient blood pressure changes associated with the drug.

Regadenoson is not a medication you 'take' in the traditional sense. It is administered by a nurse or technician during your nuclear stress test.

• Preparation: You will likely be asked to fast (not eat) for several hours before the test.
• Caffeine Restriction: It is critical to avoid all caffeine-containing products (coffee, tea, soda, chocolate, and certain over-the-counter pain relievers) for at least 12 to 24 hours before the procedure. Caffeine blocks the receptors that regadenoson targets, which can make the test results inaccurate.
• Procedure: You will lie on an imaging table, and an IV line will be started. The regadenoson will be injected quickly through the IV. You may feel a warm sensation or a brief period of shortness of breath immediately after the injection.
• Storage: In the clinical setting, regadenoson is stored at controlled room temperature (20°C to 25°C or 68°F to 77°F).

Because regadenoson is administered as a single dose by a healthcare professional during a scheduled medical procedure, the concept of a 'missed dose' as it applies to daily medications does not exist. If your procedure is canceled or delayed, your healthcare provider will reschedule the administration. If you realize you consumed caffeine before your test, notify your provider immediately, as the dose may need to be postponed to ensure an accurate test.

An overdose of regadenoson in a clinical setting is rare due to the use of pre-filled 0.4 mg syringes. However, if an excessive dose were administered, it could lead to prolonged hypotension (low blood pressure), dizziness, or heart rhythm disturbances.

• Signs of Overdose: Severe flushing, profound dizziness, fainting, or significant difficulty breathing.
• Emergency Measures: Aminophylline (a bronchodilator) may be administered intravenously by your doctor to reverse the effects of regadenoson. Aminophylline acts as a competitive antagonist to the adenosine receptors, effectively 'turning off' the effects of the drug. Supportive care, including IV fluids and heart rate monitoring, would also be provided.

> Important: Follow your healthcare provider's pre-test instructions exactly, especially regarding food and caffeine intake. Do not adjust any of your regular medications before the test without explicit medical guidance.

Most patients receiving regadenoson will experience at least one transient side effect. These symptoms usually begin within seconds of the injection and typically resolve within 15 to 30 minutes as the drug is cleared from the system.

• Dyspnea (Shortness of Breath): This is the most common side effect, occurring in nearly 28% of patients. It may feel like you cannot take a full breath or are mildly winded, similar to light exercise.
• Headache: Reported by approximately 26% of patients. It is usually described as a dull pressure or throbbing sensation.
• Flushing: A feeling of warmth, redness, or tingling in the face, neck, or chest occurs in about 16% of patients due to the widening of blood vessels near the skin.
• Chest Discomfort: About 13% of patients report pressure or tightness in the chest. While this can be concerning, it is often a direct result of the drug's effect on heart receptors rather than a heart attack, though medical staff will monitor you closely.
• Dizziness: Occurring in about 8-12% of patients, this is often related to a temporary drop in blood pressure.

These effects are less frequent but are well-documented in clinical literature:

• Nausea and Abdominal Discomfort: Some patients may feel 'sick to their stomach' or experience mild cramping.
• Paresthesia: A sensation of tingling or 'pins and needles' in the extremities.
• Fatigue: A sudden feeling of tiredness or weakness following the injection.
• Taste Perversion: A metallic or unusual taste in the mouth.
• Hypotension: A temporary decrease in blood pressure that may cause lightheadedness.

• ST-Segment Changes: Specific changes on the Electrocardiogram (ECG) that indicate heart stress.
• Arrhythmias: Abnormal heart rhythms, such as atrial fibrillation or premature ventricular contractions.
• Syncope: A temporary loss of consciousness (fainting).
• Tremor: Involuntary shaking or shivering.

While regadenoson is administered under medical supervision, certain reactions are severe and require immediate intervention by the attending physician:

• Myocardial Ischemia and Infarction (Heart Attack): In rare cases, the stress placed on the heart by the drug can trigger a heart attack, particularly in patients with severe, unstable coronary artery disease.
• Cardiac Arrest: Sudden cessation of heart function has been reported, though it is extremely rare.
• Ventricular Arrhythmias: Life-threatening heart rhythms that require emergency treatment.
• Seizures: Regadenoson may lower the seizure threshold. Patients with a history of epilepsy or those taking medications that lower the seizure threshold are at higher risk.
• Stroke (Cerebrovascular Accident): Hemorrhagic or ischemic strokes have been reported in temporal association with regadenoson.
• Severe Bronchoconstriction: While regadenoson is selective, it can still cause severe breathing difficulties in patients with advanced asthma or COPD.
• Anaphylaxis: Severe allergic reactions characterized by swelling of the throat, hives, and difficulty breathing.

> Warning: Stop the procedure and alert your medical team immediately if you experience severe chest pain, sudden weakness on one side of your body, or extreme difficulty breathing.

Because regadenoson is a diagnostic agent administered as a single dose with a very short half-life, there are no documented 'long-term' side effects associated with its use. The drug is typically fully eliminated from the body within several hours. Any symptoms that persist for more than 24 hours after the procedure should be reported to a healthcare provider, as they may be related to an underlying condition rather than the medication itself.

As of 2024, the FDA has issued warnings regarding the risk of serious adverse cardiovascular events. While not a traditional 'Black Box Warning' in the same sense as some chronic medications, the labeling includes high-level warnings for:

• Cardiac Arrest and Fatal Myocardial Infarction: These events can occur. Facilities administering regadenoson must have cardiac resuscitation equipment and trained personnel immediately available.
• Seizure Risk: New-onset or recurrence of convulsive seizures has occurred. Some seizures are prolonged and require urgent anticonvulsive management.

Report any unusual symptoms or persistent discomfort to your healthcare provider following your imaging procedure.

Regadenoson is a potent pharmacological agent that significantly alters cardiovascular dynamics for a brief period. It should only be administered in a clinical setting equipped with continuous electrocardiogram (ECG) monitoring and advanced life support equipment. Before the procedure, you must disclose your full medical history, including any history of heart rhythm disorders, lung disease, or seizures. The most critical safety aspect for the patient is the strict avoidance of caffeine for at least 12 hours prior, as caffeine can mask the results of the test and potentially lead to a false-negative diagnosis of heart disease.

There are no formal 'Black Box Warnings' (the FDA’s most stringent warning) for Regadenoson as of current 2024 labeling. However, the 'Warnings and Precautions' section of the FDA-approved label carries equivalent weight regarding the risk of fatal cardiac events and seizures. Healthcare providers are instructed to avoid use in patients with symptoms of unstable angina or cardiovascular instability, as these patients are at higher risk for serious complications during the stress test.

• Myocardial Ischemia: Regadenoson can cause a phenomenon called 'coronary steal,' where blood is diverted away from narrowed arteries toward healthy ones. This can lead to localized ischemia (lack of oxygen) in the heart muscle. If severe ischemia is detected during the test, the physician may need to administer a reversal agent like aminophylline.
• Sinoatrial and Atrioventricular (AV) Block: Adenosine receptor agonists can interfere with the heart's electrical conduction system. Regadenoson may cause heart blocks, where the electrical signal between the heart's chambers is delayed or stopped. This is particularly dangerous in patients with pre-existing conduction abnormalities.
• Hypotension and Hypertension: Most patients experience a small decrease in blood pressure, but some may experience a significant drop (hypotension). Conversely, some patients experience a sharp increase in blood pressure (hypertension). Both require careful monitoring.
• Bronchoconstriction: Although regadenoson is selective for A2A receptors, it may still trigger respiratory distress in patients with reactive airway diseases like asthma or chronic obstructive pulmonary disease (COPD). Aminophylline should be available to treat any resulting bronchospasm.
• Seizures: Use with caution in patients with a history of seizures. The medication should be discontinued and not restarted in any patient who experiences a seizure during administration.

During and after the administration of regadenoson, the following monitoring is mandatory:

• Continuous ECG: To detect any heart rhythm changes, ST-segment shifts, or heart blocks.
• Blood Pressure: Measured at regular intervals (usually every minute) until the patient's vitals return to baseline.
• Oxygen Saturation: Monitored via pulse oximetry, especially in patients with a history of lung disease.
• Symptom Assessment: The medical team will frequently ask how you are feeling to identify any early signs of adverse reactions.

While the drug itself clears the system quickly, the physical and emotional stress of the imaging procedure, combined with the required fasting, may leave some patients feeling dizzy or fatigued. It is generally recommended that patients wait until they have eaten a meal and feel fully recovered before driving. Some facilities may require you to have a designated driver if you have a history of fainting or if you receive sedative medications during the procedure.

There is no direct chemical interaction between alcohol and regadenoson. However, patients are typically instructed to avoid alcohol for 24 hours before a cardiac stress test. Alcohol can affect heart rate and blood pressure, potentially complicating the interpretation of the imaging results. Furthermore, alcohol withdrawal can lower the seizure threshold, increasing the risks associated with regadenoson.

Because regadenoson is a single-dose diagnostic agent, there is no 'discontinuation' or tapering process. Once the injection is complete and the imaging is finished, the drug naturally exits the body. There is no risk of withdrawal syndrome. If a patient experiences a severe adverse reaction during the injection, the healthcare provider will immediately stop the administration and may give a reversal agent.

> Important: Discuss all your medical conditions, especially any history of asthma, seizures, or heart rhythm problems, with your healthcare provider before starting Regadenoson.

There are specific substances that must be avoided because they directly interfere with the way regadenoson works at the receptor level:

• Methylxanthines (Caffeine, Theophylline, Aminophylline): These are competitive antagonists of adenosine receptors. If these are present in your system, they will block regadenoson from binding to the A2A receptors, potentially leading to a 'false negative' test result (where the test looks normal even if heart disease is present).
• Clinical Consequence: Reduced diagnostic efficacy and inaccurate results.
• Management: Patients must avoid caffeine and theophylline-containing medications for at least 12-24 hours before the test. Aminophylline should not be given before the test but is used as a 'rescue' drug after the test is complete.

• Dipyridamole: This medication (often used to prevent blood clots) inhibits the cellular uptake of adenosine and can increase the blood levels and effects of regadenoson.
• Clinical Consequence: Increased risk of severe side effects, prolonged vasodilation, and hypotension.
• Management: Dipyridamole should be discontinued for at least 48 hours before the administration of regadenoson, as per standard clinical protocols.

• Beta-Blockers (e.g., Metoprolol, Atenolol): These drugs slow the heart rate. While they do not prevent regadenoson from working, they may blunt the heart rate increase that typically occurs in response to the drug.
• Calcium Channel Blockers (e.g., Diltiazem, Verapamil): Similar to beta-blockers, these may affect the heart's response and increase the risk of heart block.
• Nitrates (e.g., Nitroglycerin): Since nitrates also cause vasodilation, the combination may lead to a more pronounced drop in blood pressure.
• Digoxin: When combined with regadenoson, there is a theoretical increase in the risk of AV block (heart rhythm disturbance).

• Caffeine: This is the most critical food interaction. Caffeine is found in coffee (including decaf), tea, soda, energy drinks, and chocolate. Even small amounts can interfere with the test.
• High-Fat Meals: While food does not interact with the IV injection of regadenoson, patients are usually asked to fast because a full stomach can interfere with the quality of the nuclear images of the heart.
• Grapefruit: There are no known interactions between regadenoson and grapefruit, as the drug is not significantly metabolized by the CYP3A4 enzyme.

• Guarana: This common herbal supplement contains high concentrations of caffeine and must be avoided for at least 24 hours before the procedure.
• Green Tea Extract: Often found in weight-loss supplements, this also contains caffeine and should be avoided.
• St. John's Wort: While it affects many drugs via CYP induction, it does not have a known significant interaction with the single-dose administration of regadenoson.

Regadenoson is not known to interfere with standard laboratory blood tests (such as glucose, electrolytes, or liver enzymes). However, its primary purpose is to interact with the Myocardial Perfusion Imaging (MPI) test. Its presence is required for the 'stress' portion of the lab test to be valid. If a patient has consumed caffeine, the 'lab result' of the nuclear scan may be invalidated.

For each major interaction, the mechanism usually involves competitive antagonism (like caffeine blocking the receptor) or pharmacodynamic synergism (like nitrates adding to the blood-pressure-lowering effect). Your doctor will provide a specific list of medications to hold before your appointment.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for asthma, heart rhythm, or pain relief.

There are specific medical conditions where the use of regadenoson is strictly prohibited because the risks significantly outweigh any diagnostic benefit. In these cases, the drug must NEVER be used:

• Second- or Third-Degree AV Block: Patients with these types of heart block have a failure in the heart's electrical system. Regadenoson can further depress the conduction of electrical signals, potentially leading to asystole (the heart stops beating).
• Sinus Node Dysfunction (Sick Sinus Syndrome): In patients whose 'natural pacemaker' is not working correctly, regadenoson can cause severe bradycardia (slow heart rate) or heart block.
• Exception: Patients with a functioning artificial permanent pacemaker may safely receive regadenoson, as the device will maintain the heart rate.
• Symptomatic Hypotension: Patients who already have dangerously low blood pressure should not receive the drug, as it will likely cause a further, potentially fatal, drop in pressure.
• Known Hypersensitivity: Any patient who has had a previous severe allergic reaction to regadenoson or its components must not receive it.

These conditions require a careful 'risk-benefit' analysis by the cardiologist. The test may still be performed, but with extreme caution and additional medical staff present:

• Severe Asthma or COPD: While regadenoson is A2A selective, there is a small risk of cross-reactivity with A2B receptors in the lungs, which can trigger a bronchospasm. If the patient is currently wheezing or in an acute flare-up, the test should be postponed.
• Unstable Angina: Patients whose chest pain is worsening or occurring at rest are at much higher risk for a heart attack during any form of stress testing.
• Recent Seizure: Because regadenoson can lower the seizure threshold, a recent history of seizures may make the test too risky.
• Severe Aortic Stenosis: In patients with a severely narrowed heart valve, the sudden vasodilation caused by regadenoson can lead to a dangerous drop in blood flow to the brain.

Patients who are allergic to adenosine (Adenoscan) may have a higher risk of being allergic to regadenoson, as the two molecules are chemically related. However, cross-sensitivity is not always guaranteed. If you have had a reaction to any 'stress agent' in the past, it is vital to inform your imaging team before the injection is prepared.

> Important: Your healthcare provider will evaluate your complete medical history, including an ECG performed right before the injection, to ensure no contraindications are present.

Regadenoson is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. In animal studies, high doses of regadenoson were associated with reduced fetal body weight and delays in bone development.

Because of the lack of human data and the fact that regadenoson is used for a diagnostic procedure that can often be postponed, it is generally recommended to avoid its use during pregnancy. If a pregnant woman requires a heart stress test, healthcare providers will typically look for alternative diagnostic methods that do not involve pharmacological stress or radiation (from the tracers). If you are pregnant or planning to become pregnant, you must inform your doctor before the procedure.

It is not known whether regadenoson is excreted in human milk. However, many drugs are excreted in breast milk, and because of the potential for serious adverse reactions in a nursing infant, caution is advised. Based on the drug's half-life, the risk of exposure to the infant is likely low after several hours. A common clinical recommendation is for breastfeeding mothers to 'pump and discard' breast milk for at least 10 to 24 hours after receiving regadenoson to ensure the drug has been completely eliminated from their system.

Regadenoson is not FDA-approved for use in patients under the age of 18. The safety, efficacy, and appropriate dosing for children have not been established in clinical trials. Children's cardiovascular systems and adenosine receptor densities may differ from adults, making the effects of the drug less predictable. In pediatric cardiology, exercise stress tests or other imaging modalities are preferred.

Clinical studies included a significant number of subjects aged 65 and over (approximately 34%). No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more likely to have age-related decreases in renal function. While this does not require a dose adjustment, it may slightly prolong the time the drug stays in the system. Geriatric patients may also be more susceptible to the dizzying effects of hypotension, increasing the risk of falls immediately following the procedure.

In patients with renal impairment, the clearance of regadenoson is reduced, leading to higher concentrations of the drug in the blood. For example, in patients with severe renal impairment (creatinine clearance < 30 mL/min), the drug's exposure is increased by about 38% compared to those with normal kidney function. Despite this increase, clinical trials showed that the standard 0.4 mg dose was well-tolerated and effective. No dose adjustment is needed for any degree of renal impairment, including patients on dialysis.

Specific studies in patients with hepatic impairment have not been conducted. However, because regadenoson is primarily cleared by the kidneys and does not undergo significant metabolism by liver enzymes (CYP450), hepatic impairment is not expected to significantly alter the drug's concentration or safety profile. No dose adjustments are currently recommended for patients with liver disease.

> Important: Special populations require individualized medical assessment. Always ensure your medical team is aware of your pregnancy status, kidney health, and any other unique health factors.

Regadenoson is a low-affinity agonist for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor and virtually no affinity for the A2B and A3 receptors. The A2A receptors are G-protein-coupled receptors located on the vascular smooth muscle cells of the coronary arteries. When regadenoson binds to these receptors, it stimulates the enzyme adenylate cyclase, which increases the production of intracellular cyclic AMP (cAMP).

This increase in cAMP leads to the relaxation of the smooth muscle and subsequent vasodilation of the coronary arteries. This process specifically increases coronary blood flow (CBF) without a proportional increase in myocardial oxygen consumption, which is the hallmark of a 'pharmacologic stressor.' The selectivity for A2A over A1 is clinically significant because A1 receptors are responsible for the heart-rate-slowing and AV-node-blocking effects often seen with non-selective agents like adenosine.

Following a rapid IV bolus of 0.4 mg regadenoson, coronary blood flow increases rapidly, typically reaching a peak within 30 seconds to 1 minute. The increase in blood flow is usually 2 to 3 times above the resting level. This elevated flow is maintained at a 'diagnostic plateau' for several minutes, which provides a sufficient window to inject the radiopharmaceutical tracer and for the tracer to be taken up by the heart muscle. The heart rate typically increases by about 20 to 25 beats per minute, while systolic blood pressure may decrease by about 10 mmHg. These effects usually return to baseline within 15 to 30 minutes.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | ~12% (Primarily Albumin) |

| Initial Half-life | 2 to 4 minutes |

| Intermediate Half-life | ~30 minutes |

| Terminal Half-life | ~2 hours |

| Tmax (Peak Effect) | 0.5 to 1 minute |

| Metabolism | Minimal (Not CYP-dependent) |

| Excretion | Renal 57% (Unchanged), Fecal 43% |

• Molecular Formula: C15H18N8O5
• Molecular Weight: 390.35 g/mol
• Solubility: Sparingly soluble in water and ethanol.
• Structure: Regadenoson is a 2-substituted adenosine derivative. It contains a pyrazole ring attached to the adenosine core, which provides its high selectivity for the A2A receptor. It is chemically described as 1-(6-amino-9-beta-D-ribofuranosyl-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide.

Regadenoson is categorized therapeutically as a diagnostic radiopharmaceutical adjunct and pharmacologically as an Adenosine Receptor Agonist [EPC]. It is the first selective A2A agonist approved for clinical use. Related medications include adenosine (non-selective) and dipyridamole (an indirect adenosine booster), though regadenoson's fixed-dosing and selectivity profile make it unique within this class.